Search
for
Sort by
Research 61–90 of 227
- 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
- Pharmacotherapy of alopecia areata
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- JAK Inhibitors for Treatment of Alopecia Areata
- Role of janus kinase inhibitors in the treatment of alopecia areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- A novel therapeutic paradigm for patients with extensive alopecia areata
- New drugs under investigation for the treatment of alopecias
- An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- Current and future pharmacotherapy for alopecia areata
- The role of janus kinases in the treatment of autoimmune skin diseases
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Clinical Perspectives on Alopecia: From Hair Follicle Biology to Advanced Therapies
- Theoretical investigation on the construction of hair follicle membranes and the transdermal drug delivery mechanisms of JAK inhibitors via distinct pathways
- JAK-centric explainable few-shot gene-expression diagnosis framework for alopecia via MultiPLIER priors and relation-style set-to-set comparison
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- Ritlecitinib: First Approval
- Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options
- Sterol Intermediates of Cholesterol Biosynthesis Inhibit Hair Growth and Trigger an Innate Immune Response in Cicatricial Alopecia
- Advances in the Molecular Pathogenesis and Targeted Therapy of Psoriasis
- Farmácia Padrão da Légua, Custóias e nos Serviços Farmacêuticos da Klinicka Bolnica Dubrava, Croácia
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population